CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SuraminWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug106 AT-527 Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.23

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.23

There is one clinical trial.

Clinical Trials

1 A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI

This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.

NCT04496596 Acute Kidney Injury Drug: Suramin Drug: Placebo
MeSH:Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: The difference between the effect of a 3.0 mg/kg infusion of suramin versus placebo will be based on meeting 2 or more of the composite event endpoints of: peak serum creatinine (Cr) of 6 mg/dL or above from investigational product (IP) infusion through Day or progression to KDIGO Stage III within 72 hours (hr) from IP infusion or death or dialysis from IP infusion through Day 7.

Measure: To evaluate and compare the efficacy of a single 3.0 mg/kg infusion of suramin versus placebo in subjects with diuretic unresponsive AKI

Time: 7 days

Related HPO nodes (Using clinical trials)

HP:0001919: Acute kidney injury
Genes 29
STOX1 TCN2 DGKE SAA1 CFH LPIN1 CD46 C3 CD46 FLT1 CACNA1S CFB RYR1 CFH APRT HPRT1 HNF1B CCND1 CORIN CFHR1 HELLPAR CFI SLC26A1 THBD PYGM CFHR3 HNF4A CFI SLC22A12
Protein Mutations 0
SNP 0